|Articles|July 15, 2002
Miravant results revived: Bausch & Lomb to review potential AMD drug
Santa Barbara, CA-Bausch & Lomb will review results of Miravant Medical Technologies' SnET2 trials with an option to negotiate the exclusive worldwide license to develop and commercialize the drug for the treatment of wet age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
2
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
3
Corza Medical announces launch of the SensorTek ROP Kit
4
EyePoint receives second consecutive positive recommendation from DSMC
5














































.png)


